The purpose of the Coleman Institute for Cognitive Disabilities is to catalyze and integrate advances in technology to promote the quality of life of people with cognitive disabilities. Approximately 30 million people in the U.S. have a cognitive disability such as intellectual disability, brain injury, Alzheimer's disease, stroke, and serious, persistent mental illness. An estimated 449,000 persons in Colorado alone have cognitive disabilities.
The Institute supports research, development, dissemination, and education in cognitive disabilities on campuses of the University of Colorado in Boulder, Colorado Springs, Denver, and the Anschutz Medical Campus in Aurora. We are committed to providing scientific, technological, and public policy leadership to strengthen the voice of persons with cognitive disabilities and their families in our society.
The Coleman Institute for Cognitive Disabilities was established in 2001 by the Regents of the University of Colorado. A private endowment and sustained annual contributions by our founding donors, William T. and Claudia L. Coleman, support the Institute's activities through the Coleman Colorado Foundation (CCF). The CCF is a 501 (c) (3) public charity. It is classified as a 509 (a) (3) supporting organization to the University of Colorado (CU) to support the Coleman Institute.
The Executive Director of the Institute is David Braddock, PhD, a Senior Associate Vice President of the University of Colorado System. He holds the Coleman-Turner Chair in the School of Medicine, Department of Psychiatry at CU's Anschutz Medical Campus. The Associate Director is Emily Shea Tanis, PhD, who serves as an Assistant Professor, Department of Psychiatry at CU's Anschutz Medical Campus.